about
Aptamers in TherapeuticsAptamers: A Feasible Technology in Cancer ImmunotherapySelection and Biosensor Application of Aptamers for Small MoleculesFrom selection hits to clinical leads: progress in aptamer discoveryMolecular Selection, Modification and Development of Therapeutic Oligonucleotide AptamersTargeting Th17 Cells with Small Molecules and Small Interference RNAFluorescence anisotropy (polarization): from drug screening to precision medicine.Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesAptamers in diagnostics and treatment of viral infectionsFrom ugly duckling to swan: unexpected identification from cell-SELEX of an anti-Annexin A2 aptamer targeting tumorsManipulating the in vivo immune response by targeted gene knockdownssDNA Aptamer Specifically Targets and Selectively Delivers Cytotoxic Drug Doxorubicin to HepG2 CellsNot so pseudo anymore: pseudogenes as therapeutic targetsModulation of the Coagulation Cascade Using AptamersIn vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugsPlatelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Analyzing HT-SELEX data with the Galaxy Project tools--A web based bioinformatics platform for biomedical research.Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancerNanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease TherapyProgress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.Characterization of an RNA aptamer against HPV-16 L1 virus-like particlesCell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization.Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamerAptamer photoregulation in vivoAntibody- and aptamer-strategies for GvHD prevention.Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth.FASTAptamer: A Bioinformatic Toolkit for High-throughput Sequence Analysis of Combinatorial Selections.Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cellsLarge scale analysis of the mutational landscape in HT-SELEX improves aptamer discoveryIsolation of Foreign Material-Free Endothelial Progenitor Cells Using CD31 Aptamer and Therapeutic Application for Ischemic Injury.Selective Targeting to Glioma with Nucleic Acid AptamersLigand-targeted theranostic nanomedicines against cancerAFBI assay - Aptamer Fluorescence Binding and Internalization assay for cultured adherent cells.The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation.High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency.In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies
P2860
Q26738413-F988A464-F378-43FF-BE59-E75A32DC07D6Q26740303-61380B11-CE21-4975-B43F-650CADC5CA21Q26744467-F9F6235D-2834-4876-9463-5C35B6F3BB4CQ26752799-1705F227-9636-4B12-B820-56666DC53E55Q26765458-AF8AEEAE-C796-400C-9022-CEAC04E186FEQ26770523-02F6D22D-73B3-4E53-AE1B-2ABC303EA545Q26796399-7B3FFF4E-6D08-45A8-AC61-35262F91189DQ26825644-C769DE02-E264-41C1-94CF-4E360BADBFC3Q26995399-F10C4660-43B9-4934-9703-FD56EDE0ECC4Q27014527-A25C11CF-3254-48D1-B641-CE317502A598Q27326068-21D9E2A4-3B8D-418E-BCF6-061B9D062B2DQ28083494-B4BB0F77-2F84-4E65-B422-B931331B41E8Q28552859-29198CE4-9338-4EE1-9174-B3A4CA7E7D51Q28657757-E9FCA1F8-0E33-4FEB-A061-31112ECE0A14Q28816936-DC27C3E3-6239-412D-9691-E254BFC9135FQ28828886-0FB2194D-EE58-4446-8A24-E2463FD4DBD1Q30250273-B4D7EC15-5B87-4A70-9114-A9A674C4703DQ31007883-9410DDAB-55F2-4E53-9EEE-165561AC88D2Q33584756-0ACB5F1E-ABCD-4A6D-BA3C-9A82C8B6365DQ33681168-38652AF0-6347-46AF-A120-DC6BDF8BC822Q33834772-B7D2A3DC-AF77-4D3A-A1C0-502269475F5CQ33935498-C3034088-6652-4185-BC87-06DAAC7BE3DCQ34171663-879CF229-395C-4617-830B-63D111E6974CQ34232003-2AADEE3A-6443-4055-BE91-E1343FC7FA6FQ34459376-C7C87A22-DFE9-463F-8DDB-925A9FA30417Q34474963-AFD402CF-D98E-47D5-AC57-3F988C5AF635Q34661329-79595548-EB97-43AF-B282-1ED6C9A9ECB7Q34885269-3716D6A3-28A7-4A8A-97B7-80B41F689451Q35148896-FC3CC1BD-E546-4F53-ADBA-FC371D2B3C10Q35161360-6E578850-512F-4F17-A9A7-D54B800A4D25Q35205365-CCF56DDB-5E43-45EC-80FD-ACF487AEB25CQ35335653-C1054A1D-43D6-49BC-A3B3-A29832419E32Q35600644-37ECB68A-C5E4-45F6-A64C-CCACE8BD6732Q35684128-9BBDD9BF-4371-4CFB-91CA-9D45DF0CE8FEQ35740074-91272B5D-952C-44E2-9363-1B204C6A5483Q35895637-471FB987-DBE9-48DD-B217-9B85D0A96182Q35955516-BA33DA47-6255-4C04-836B-E489AF36C8BFQ35961417-8DDC497C-03E2-43E8-93A8-CC5280AE682FQ36139325-F7CF9EF0-410B-4184-8F8F-9E5D215E5DF8Q36156320-B33AD5AD-2FE2-4119-918C-F069EB3F3D74
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Therapeutic RNA aptamers in clinical trials.
@en
type
label
Therapeutic RNA aptamers in clinical trials.
@en
prefLabel
Therapeutic RNA aptamers in clinical trials.
@en
P2093
P1476
Therapeutic RNA aptamers in clinical trials.
@en
P2093
Helena Kurniawan
Jacek Wower
Mark E Byrne
Padma Sundaram
P304
P356
10.1016/J.EJPS.2012.10.014
P407
P577
2012-11-07T00:00:00Z